Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:2789:161-169.
doi: 10.1007/978-1-0716-3786-9_17.

Detection of Antigen Presentation by Murine Bone Marrow-Derived Dendritic Cells After Treatment with Nanoparticles

Enping Hong  1 , Marina A Dobrovolskaia  2
Affiliations

Detection of Antigen Presentation by Murine Bone Marrow-Derived Dendritic Cells After Treatment with Nanoparticles

Enping Hong et al. Methods Mol Biol. 2024.

Abstract

Nanoparticles are frequently considered in vaccine applications due to their ability to co-deliver multiple antigens and adjuvants to antigen-presenting cells. Some nanoparticles also have intrinsic adjuvant properties that further enhance their ability to stimulate immune cells. The delivery of tumor-specific antigens to antigen-presenting cells (APCs) with subsequent antigenic peptide presentation in the context of class I major histocompatibility complex (MHC-I) molecules represents an essential effort in developing nanotechnology-based cancer vaccines. Experimental models are, therefore, needed to gauge the efficiency of nanotechnology carriers in achieving peptide antigen delivery to APCs and presentation in the context of MHC-I. The assay described herein utilizes a model antigen ovalbumin and model APCs, murine bone marrow-derived dendritic cells. The 25-D1.16 antibody, specific to the ovalbumin (OVA) MHC-I peptide SIINFEKL, recognizes this peptide presented in the context of the murine H2-Kb class I MHC molecule, allowing the presentation of this antigen on APCs to be detected by flow cytometry after nanoparticle delivery.

Keywords: Antigen presentation; Dendritic cells; Nanoparticles; Vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Hashemi Goradel N, Nemati M, Bakhshandeh A, Arashkia A, Negahdari B (2023) Nanovaccines for cancer immunotherapy: focusing on complex formation between adjuvant and antigen. Int Immunopharmacol 117:109887 - DOI - PubMed
    1. Hong E, Dobrovolskaia MA (2019) Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. Adv Drug Deliv Rev 141:3–22 - DOI - PubMed
    1. Vishweshwaraiah YL, Dokholyan NV (2022) mRNA vaccines for cancer immunotherapy. Front Immunol 13:1029069 - DOI - PubMed - PMC
    1. Yi Y, Yu M, Li W, Zhu D, Mei L, Ou M (2023) Vaccine-like nanomedicine for cancer immunotherapy. J Control Release 355:760–778 - DOI - PubMed
    1. Zhang X, Yang B, Ni Q, Chen X (2023) Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev 52(9):2886–2910 - DOI - PubMed

LinkOut - more resources